Thrombin participates in coagulation, anticoagulation, and initiation of platelet activation. To fulfill its diverse roles and maintain hemostasis, this serine protease is regulated via the extended active site region and anion-binding exosites (ABEs) I and II. For the current project, amide hydrogen-deuterium exchange coupled with MALDI-TOF mass spectrometry was used to characterize ligand binding to individual exosites and to investigate the presence of exosite-active site and exosite-exosite interactions. PAR3(44–56) and PAR1(49–62) were observed to bind to thrombin ABE I and then to exhibit long range effects over to ABE II. By contrast, Hirudin(54–65) was used to characterize ligand binding to individual exosites and to investigate the presence of exosite-active site and exosite-exosite interactions. PAR3(44–56) and PAR1(49–62) were observed to bind to thrombin ABE I and then to exhibit long range effects over to ABE II. By contrast, Hirudin(54–65) was observed to bind to thrombin ABE I and then to exhibit long range effects over to ABE II. In addition to the autolysis loop often focused more on ABE I and did not transmit influences over to ABE II. Although these three ligands were each directed to ABE I, they did not promote the same conformational consequences.

To achieve this balance, thrombin contains insertion loops and two anion-binding exosites (ABE)\(^3\) that cause it to be a more selective enzyme than other members of the serine protease family (1, 2). The 60-insertion (or \(\beta\)-insertion) loop functions like a lid regulating entrance into the active site, and the autolysis (or \(\gamma\)) loop participates in controlling substrate specificity. Removal of the autolysis loop leads to a thrombin mutant with greatly hindered ability to convert fibrinogen to fibrin (4). In addition to the \(\beta\) - and \(\gamma\)-loops, thrombin exosites ABE I and ABE II also play key roles in regulating substrate specificity (Fig. 1). Exosite binding has been shown to direct substrates to the active site, contribute to opening of the active site region, and help in attracting other regulatory molecules to thrombin. Targeting ligands to these ABEs promotes local and/or long range conformational changes to thrombin. Together, these different actions allow thrombin to fulfill its array of protease functions (3).

Both thrombin ABEs are highly positively charged and are located on opposite sides of the serine protease active site (Fig. 1) (5). ABE I contains some additional hydrophobic character relative to ABE II. ABE I is utilized by fibrinogen, thrombomodulin (TM), protease-activated receptors PAR1 and PAR3, and the leech-derived thrombin inhibitor Hirudin. The opposite exosite ABE II accommodates heparin, sulfated benzo-furans, fibrinogen \(\gamma\), Factor VIII, and the platelet receptor GpIba(1–3, 6).

The ability of exosite interactions to influence events at the thrombin active site is well established (7–9). The presence and consequence of long range communication between exosites, however, is not fully defined. Studies in this research area have often focused on fluorescence and/or surface plasmon resonance effects. Some reports indicate that thrombin can readily accommodate ligands at both exosites (7, 10, 11). With these examples, the conversion from a binary (enzyme-ligand) to a
Exosite Interactions in Thrombin

FIGURE 1. Highlighting key sites on the serine protease thrombin. The catalytic triad, the anion-binding exosites, and the autolysis loop are marked in black. The catalytic triad is represented by Ser195, His57, and Asp102 and shown as sticks. The anion-binding exosites of thrombin (ABE I and ABE II) are located at opposite sides of the active site and are shown as sticks. The Protein Data Bank code was 1PPB. The figure was prepared with PyMOL.

 ternary (ligand 1-enzyme-ligand 2) complex does not lead to major changes in the $K_D$ value of either ligand. By contrast, other investigations suggest that binding at one exosite can greatly hinder binding events at the opposite exosite (12, 13). As a result, ternary complexes are challenging to maintain. The discrepancies in these different results may be due to the individual ligands tested and/or the environments in which the complexes are examined.

An alternative approach utilizes amide proton hydrogen-deuterium exchange (HDX) coupled with mass spectrometry to characterize ligand binding to thrombin exosites in solution (14–19). The HDX method focuses on documenting the exchange of solvent-accessible backbone amide protons with heavier deuterons. Unlike the fluorescence and surface plasmon resonances studies, no bulky spectroscopic probes are utilized. Fluorescence and surface plasmon resonances studies, no bulky spectroscopic probes are utilized. Unlike the fluorescence and surface plasmon resonances studies, no bulky spectroscopic probes are utilized. Unlike the fluorescence and surface plasmon resonances studies, no bulky spectroscopic probes are utilized.

With the HDX technique, it is possible to assess which regions of the protein become more or less exposed to solvent in the presence versus the absence of ligand. Our previous HDX data demonstrated that binding of either GpIbα(269–286) or fibrinogen γ(410–427) to ABE II led to distinctive interexosite communication over to ABE I (15, 16). By contrast, other HDX studies showed that binding of Hirudin(54–65) to ABE I did not cause the same kind of extensive long range effect to ABE II (16). Interestingly, recent NMR studies (20, 21) have further documented that thrombin is a highly flexible molecule in solution whose conformations can be modulated upon introduction of ligands.

In light of these HDX-MS and NMR results, it is very intriguing to further characterize interexosite communication in thrombin and the contributions made by individual ligands. To achieve this goal, we employed HDX coupled with MALDI-TOF mass spectrometry to explore three important ideas. First, we examined the ability of peptides derived from PAR1 and PAR3 to target ABE I and then influence the solvent accessibil-
There are some sequence differences between bovine and human thrombin within the autolysis loop region. These differences result in some changes in proteolytic cleavage sites. However, peptic digests involving the autolysis region do yield overlapping segments (bovine residues 135–149D versus human residues 131–144 and 145–155; chymotrypsin numbering). As a result, information can still be collected on the full loop region. Prior hydrogen deuterium exchange studies demonstrated that the same conformational conclusions could be made with both thrombin forms (17, 28). Moreover, the autolysis loops reported on similar changes in solvent accessibility. The bovine-derived autolysis segment has the added benefit of being easier to detect and quantitate by MALDI-TOF mass spectrometry than the human segments.

**HDX Sample Preparation**—Thrombin was buffered exchanged into 75 mM NaCl, 12.5 mM NaH₂PO₄, pH 6.5. The enzyme solution was then concentrated to 50 µM, a value verified by UV measurements on a Cary 100 spectrophotometer. The more physiological buffer concentrations of 150 mM NaCl and 25 mM NaH₂PO₄ would later be achieved by drying down thrombin aliquots and resuspending them in a smaller volume of D₂O. The resolubilized thrombin maintained 80% of its original activity toward the chromogenic substrate Pefachrome TH (H-D-CHG-Ala-Arg-p-nitroanilide). Moreover, this thrombin sample could still readily clot fibrinogen as measured by a turbidity assay (see supplemental Fig. S1). A key cleavage site used to generate ligand-impaired γ-thrombin occurs at the Arg⁷⁷⁶-Tyr⁷⁷⁷ site (31). With the resolubilized thrombin samples, the ABE I segment containing residues 65–84 was still intact and could be isolated from thrombin following a peptic digest. The thrombin used in the current HDX studies must therefore still have the ABE I residues 65–84 available for ligand binding.

Solution aliquots of buffer-exchanged thrombin (50 µM) were incubated with ligands of interest for 10 min at room temperature. Hirudin (54–65), PAR1 (49–62), and GpIbα (269–286) peptides were added to thrombin at 20:1 ratios, whereas PAR3 (44–56) and Fbg γ’ (410–427) were added at a 40:1 ratio.

The enzyme to ligand ratios that were chosen would help assure full occupancy of a thrombin exosite during the course of the HDX experiment. Under these conditions, a maximal amount of solvent protection at the targeted exosite could be observed after 1 min of deuteration. With the PAR peptides, 99.9% occupancy should be achieved with a 40:1 PAR3 (44–56) to thrombin ratio and a 20:1 PAR1 (49–62) to thrombin ratio (14). A considerable deterioration in mass spectral quality occurred when a 40:1 PAR1 (49–62) to thrombin ratio was used. The ratios used in this project should allow both PAR peptides to exhibit similar contact times with the thrombin surface as part of an enzyme-ligand complex.

With high ratios of ligand to enzyme, there may be concerns that nonspecific effects are being promoted. Titration control studies were carried out with the PAR peptides. As shown in supplemental Fig. S2, the overall conformational events were still preserved when the PAR1 (49–62) to thrombin ratios were lowered from 20:1 to 10:1. Nonspecific binding effects that are only present at high ligand concentrations have not been observed. With higher affinity ligands such as our previous work with GpIbα (1–290), a lower ligand to thrombin ratio of 2:1 can be monitored. The GpIbα domain could still maintain the same local and long range HDX effects as observed with the GpIbα (269–286) peptide model (16).

Control studies to assess whether an ABE I-directed ligand could also bind to another site are also valuable. A strategy to alleviate this concern would be to work with a thrombin species where the ABE I site is no longer available for ligand binding. This condition may be achieved by using γ-thrombin, a proteolytically derived variant of this serine protease that contains a disrupted ABE I region (31). With this variant, the ABE II region would be intact. Control HDX experiments were thus performed with human γ-thrombin (Hematologic Technologies, Inc.) and a series of the peptide ligands. The ligand to thrombin ratios were the same as those used for α-thrombin. The fragments resulting from peptic digest of human γ-thrombin were identified by MS/MS analysis on an Applied Biosystems 4700 mass spectrometer.

An alternative strategy to monitor for nonspecific binding to ABE II would be to employ a very high affinity ligand that targets ABE I. A candidate has not yet been found that fully blocks ABE I, does not risk interfering with ABE II regions probed by HDX, and does not promote long range effects. For HDX studies, γ-thrombin was found to serve as the best control for blocking access to ABE I.

After the single ligand complexes were examined, a series of double ligand complexes were probed in the presence of α-thrombin. Hirudin (54–65) was added first to the thrombin solution, and the mixture was incubated for 10 min at room temperature. The second ligand was then introduced, and the resultant ternary complex was incubated for an additional 10 min. For studies on active site-inhibited thrombin, PPACK was added to thrombin at a ratio of 4:1, and the mixture was incubated at 37 °C for 30 min. Inhibition of thrombin activity was verified by kinetic assay using the chromogenic substrate Pefachrome TH. The PPACK-inhibited thrombin was then subjected to buffer exchange and concentration. Later, exosite-directed ligands could be introduced.

After the different thrombin-ligand incubation periods, all complexes were dried as aliquots using a CentriVap concentrator and CentriVap cold trap (Labconco). These dried samples were stored at −70 °C for future use.

**HDX Experiments**—Dry aliquots were defrosted and allowed to come to room temperature. 12 µl of 99.996% D₂O (Cambridge Isotope Laboratories) were added, yielding final concentrations of 100 µM thrombin, 150 mM NaCl, and 25 mM NaH₂PO₄, pH 6.5. The samples were incubated in a desiccator at room temperature. After 1 min of incubation, 6 µl of sample were added to 57 µl of 0.1% TFA, pH 2.5 (on ice), to quench the exchange. The 63 µl of the quenched solution were transferred to a tube of activated pepsin bound to agarose. The remaining 6 µl of sample were quenched after 10 min of HDX and added to another tube of pepsin. Digestion occurred on ice for 10 min. The enzyme digest was separated from the pepsin-immobilized agarose by performing a centrifugation step in a mini-centrifuge kept on ice. Aliquots of 8.2 µl were immediately frozen in liquid nitrogen.

**HDX Analysis**—Each frozen aliquot of thrombin that had been subjected to HDX was thawed and immediately mixed
Exosite Interactions in Thrombin

with 8 μl of matrix (10 mg/ml α-cyano-hydroxycinnamic acid (Aldrich) in 1:1 ethanol:acetonitrile:0.1% TFA), pH 2.2. 0.5 μl of the resultant mixture were spotted onto a chilled stainless steel MALDI plate, dried with a SpeedVac unit (Savant), and inserted into the MALDI-TOF MS. This procedure was completed within a 5-min time frame, limiting the amount of hydrogen back exchange.

All of the spectra were collected in reflector mode with 256 shots/spectrum and a 800–3500 m/z range. At least three spectra were collected for each trial, and each trial was repeated at least three times. Time points for 1 and 10 min of deuteration were examined.

Data Explorer software (Applied Biosystems) was used to analyze the obtained spectra. All of the bovine thrombin peptides in the peptic digest were previously identified by Croy et al. (28), and the identities were verified in our laboratory by using post-source decay sequencing (15). All of the spectra were calibrated using two reference peptides, including the singly protonated monoisotopic mass 888.4943 Da (46–52 residues) and singly protonated pentaicositopic mass 2106.1505 Da (85–99 residues). The amount of deuterium uptake by each peptide was quantified as described by Sabo et al. (15, 16).

The number of deuterons (D) and the accompanying standard deviations were calculated for free thrombin, PPACK-inhibited thrombin, and the single versus double-ligand bound thrombin. Next, two-tailed t tests were performed on the D ± S.D. series, and the p values were calculated. As part of this work, pooled standard deviations (S_AB) were determined, and t_cali values were tabulated. Four degrees of freedom were employed. For the single ligand studies, comparisons were made relative to free thrombin. Select comparisons were also made relative to PPACK-thrombin or to one of the ligand-thrombin complexes. The data were then ranked as p ≤ 0.05 (*, 95% confidence; 2.78 < t_cali < 4.58), p ≤ 0.01 (**, 99% confidence; 4.60 < t_cali < 8.57), p ≤ 0.001 (***, 99.9% confidence; t_cali ≥ 8.61).

RESULTS

Monitoring Shifts in HDX Centroids in Presence of Ligand—HDX coupled with mass spectrometry provides an opportunity to further examine the conformational dynamics associated with the binding of ligands to thrombin. In this HDX technique, the exchange primarily of solvent-accessible backbone amide protons with heavier deuterons is detected as an increase in centroid mass (in terms of m/z) for a protein fragment (32). Upon complex formation, some regions of the intact protein can become protected from deuteration as a result of direct interaction with the ligand. The affected region becomes less accessible to the heavier deuterium and is recorded by mass spectrometry as a decrease in centroid mass compared with the same region of a deuterated ligand-free protein. In addition to detecting binding interfaces, HDX protection can be due to ligand-induced conformational changes that are propagated to distant sites (14, 18, 32).

The quenching conditions for the HDX experiments (pH 2.5 and low temperature) are well suited for pepsin-dependent cleavage of thrombin. The resultant sequence coverage allows several key thrombin regions to be probed by the HDX method.

For the current work, we quantified deuteration profiles for ABE I fragment 65–84; three ABE II fragments 85–99, 106–116, and 202–207; ABE I fragment 65–84 and 106–116; and for PAR3 fragment 44–56, PAR1(49–62), PPACK, fibrinogen γ’(410–427), and Gplba(269–286) are depicted as black sticks. Thrombin fragments obtained by peptic digest that represent ABE I, ABE II, autoysis loop, 106–116 and 202–207 regions are colored in red, dark blue, green, cyan, and orange, respectively. The catalytic triad is shown as sticks in yellow for the Ila-PPACK complex. Protein Data Bank codes include 1HAH for Hirudin(54–65), 2PUX for PAR3(44–56), 1PPB for PPACK, 2HWL for fibrinogen γ’(410–427), and 1P8V for Gplba(269–286). The figure was prepared with PyMOL.

Following HDX Centroids for Different ABE-directed Peptides—In agreement with previous thrombin-ligand crystal structures (Fig. 2), binding of the individual ligands Hirudin(54–65), PAR3(44–56), and PAR1(49–62) to thrombin each caused the centroid for the ABE I 65–84 segment to shift to lower m/z at 1 min of deuteration because of direct solvent protection at this thrombin exosite (Fig. 3). At the same time, the ABE II(85–99) was not solvent protected by Hirudin(54–65). By contrast,
PAR3(44–56) and PAR1(49–62) caused definite centroid shifts for both ABE I(65–84) and the more distant ABE II(85–99) at 1 min of deuteration (Fig. 3). The current HDX results thus suggest that the PAR3 and PAR1 segments induce both local and longer range conformational effects to thrombin.

A control experiment was then carried out using ABE I impaired γ-thrombin and a set of peptide ligands. The disrupted ABE I region could not be monitored, but any solvent protection at the key ABE II regions could be documented. Fig. 4 shows 1-min HDX centroids for γ-thrombin complexes involving Hirudin(54–65), PAR3(44–56), or GpIbα(269–286). GpIbα(269–286), an ABE II ligand, was the only peptide that could target residues 85–99 and protect this thrombin segment from deuteration. Such studies helped verify that PAR3 was not switching its dominant solvent protection effect from ABE I to ABE II when the impaired γ-thrombin was employed. For HDX studies, γ-thrombin was found to serve as the best control for blocking access to ABE I.

Based upon the γ-thrombin control studies described above, the influences of PAR3(44–56) on the native α-thrombin are proposed to be due to PAR3(44–56) targeting ABE I and then exhibiting some long range effects over to ABE II and other regions. The same results are anticipated for PAR1(49–62). Although comparing HDX centroid shifts is highly valuable, determination of the actual deuterium uptake yields more quantitative results.

**Deuteration Values for ABE I Ligands**—In the presence of Hirudin(54–65), the number of deuterons incorporated into the thrombin ABE I 65–84 region was indeed less than in free thrombin. Deuteration (D) values for residues 65–84 at 1 min included 6.81 ± 0.29 D for free thrombin versus 3.36 ± 0.17 D for Hirudin(54–65)-thrombin and then 7.80 ± 0.50 D versus 4.43 ± 0.13 D, respectively, at 10 min (p values of ≤ 0.001) (Fig. 5 and supplemental Table S1). The other regions of thrombin displayed modest, if any, differences in D across the 1–10-min time course.

PAR3(44–56) exhibited a quite different binding pattern from Hirudin(54–65). As expected, there was protection observed for ABE I 65–84 (7.63 ± 0.41 D for free thrombin versus 2.74 ± 0.25 D for thrombin-PAR3 at 1 min and then 7.97 ± 0.45 D versus 3.98 ± 0.26 D at 10 min). Interestingly, the ABE II segments 85–99, 173–180, and 173–181 were also significantly protected by the PAR3 segment. Long range solvent protection was maintained after 10 min of deuteration for ABE I, ABE II, and ABE III (Fig. 6 and supplemental Table S2). The p values for these four thrombin segments ranged from p < 0.01 to 0.001. Other regions of thrombin that underwent substantial solvent protection in the presence of PAR3(44–56) included thrombin segments 13 to −4, 106–116, 106–116, and 202–207. The autolysis loop segment 135–149D experienced a modest decrease in D across the 1–10-min deuteration period, p < 0.05 (Fig. 6 and supplemental Table S2).

The binding patterns of PAR1(49–62) were similar to PAR3(44–56). Introduction of PAR1(49–62) led to a significant decrease in deuteration for the ABE I fragment 65–84 (6.25 ± 0.27 D versus 4.37 ± 0.19 D at 1 min, p < 0.001; Fig. 7 and supplemental Table S3). With the PAR1 complex, solvent protection was also observed with thrombin ABE II residues 85–99, 173–180, and 173–181. More modest decreases in deuteration were observed for the 106–113 fragment of thrombin.

**Evaluating the Influence of Active Site Binding**—To investigate whether occupation of the active site would influence the binding pattern of the ABE I ligands, PPACK, an irreversible...
ible active site inhibitor of thrombin, was introduced prior to the addition of the ligands. By 10 min of deuteration, the presence of PPACK had consistently protected the ABE II fragment 173–181 from solvent exchange (p values /H11021 0.05 to 0.01; see Figs. 5–7 and supplemental Tables S1–S3). The N-terminal portion of PPACK is directed toward this area that borders the thrombin active site region. In addition, modest protection could at times be documented for the thrombin fragments 85–99 and 135–149D. Previous HDX studies also reported effects on these three thrombin fragments (15, 28).

The solvent protection observed for thrombin fragments 173–180 and 173–181 in the presence of PPACK was further maintained upon the addition of Hirudin(54–65). Interestingly, the autolysis loop fragment 135–149D appeared to exhibit a more than additive protection in the ternary thrombin-PPACK-Hirudin(54–65) complex following 10 min of deuteration, p < 0.001. Other thrombin segments that were protected within the thrombin-PPACK-PAR3(44–56) complex included 65–84, 85–99, 106–116, 173–181, and 202–207 (p values ranged from 0.05 to 0.001). A comparison of the deuteration values of IIa-PPACK versus IIa-PPACK-PAR3(44–56) further highlights the contributions that PAR3(44–56) makes on several local and long range regions on thrombin. PAR3(44–56) introduces its own effects even in the presence of the active site inhibitor PPACK. For the PAR1(49–62) studies, the protective effects in the presence of PPACK-thrombin focused on 65–84, 85–99, 135–149D, and 173–181 (Fig. 7 and supplemental Table S3).

Characterizing Thrombin Complexes Involving Both Anion-binding Exosites—To probe dual occupation of the exosites, HDX experiments were carried out where Hirudin(54–65) is directed to ABE I, and then GpIb/H9251(269–286) or fibrinogen γ’(410–427) is directed to ABE II. First, interactions only involving the ABE II directed ligands were examined. As expected from prior crystal structures (Fig. 2), the ligands GpIbα(269–286) and fibrinogen γ’(410–427) are targeted in the ABE II region. 10 min of deuteration, p < 0.01. For the PAR3(44–56) investigations (Fig. 6 and supplemental Table S2), PPACK inhibition appeared again to exhibit a more than additive protection on the 135–149D segment in the ternary complex following 10 min of deuteration, p < 0.001. Other thrombin segments that were protected within the thrombin-PPACK-PAR3(44–56) complex included 65–84, 85–99, 106–116, 173–181, and 202–207 (p values ranged from 0.05 to 0.001). A comparison of the deuteration values of IIa-PPACK versus IIa-PPACK-PAR3(44–56) further highlights the contributions that PAR3(44–56) makes on several local and long range regions on thrombin. PAR3(44–56) introduces its own effects even in the presence of the active site inhibitor PPACK. For the PAR1(49–62) studies, the protective effects in the presence of PPACK-thrombin focused on 65–84, 85–99, 135–149D, and 173–181 (Fig. 7 and supplemental Table S3).
vent protection was also observed at ABE I 65–84 after 1 min of deuteration (p < 0.01) but was diminished by 10 min.

HDX control studies with γ-thrombin (Fig. 4) verified that ligand binding to ABE II is not dependent on the presence of an intact ABE I. Prior NMR studies on the binary fibrinogen γ’(410–427) to γ-thrombin complex could only demonstrate that thrombin contact sites were maintained in the presence of a species with a disrupted ABE I (15). The current HDX studies on γ-thrombin revealed that the Gplβα and fibrinogen γ’ ligands were still protecting ABE II from hydrogen-deuterium exchange (see Fig. 4 for centroid shifts involving Gplβα (269–286) in the presence of γ-thrombin). By contrast, when both exosites are intact as in γ-thrombin, long range influences from ABE II to ABE I are possible.

For the ternary complexes (Gplβα-IIa-Hirudin(54–65) and Fbg γ’-IIa-Hirudin(54–65)), solvent protection at ABE I and ABE II was strongly maintained for the full 10 min of deuteration. Such results are consistent with each exosite being occupied by its preferred ligand. With these thrombin systems, protection was also observed for the thrombin fragments 106–113, 106–116, 173–180, 173–181, and 202–207 at 1 min and/or 10 min of deuteration (p values range from <0.05 to <0.001). For the current ternary complexes, the ABE II ligands appeared to exert a greater influence on the conformational dynamics of thrombin than the ABE I ligand Hirudin(54–65). As a result, the ABE II-directed ligands dominated the HDX effects observed.

**DISCUSSION**

**Probing Conformational Events after ABE I Binding**—X-ray crystallography and site-directed mutagenesis studies have indicated that Hirudin, PAR3, and PAR1 all target similar regions of thrombin ABE I (33–42). Our HDX studies effectively complement this analysis by showing solvent protection for the thrombin segment 65–84 in the presence of Hirudin(54–65), PAR3(44–56), and PAR1(49–62).

Distinct characteristics for the different ABE I ligands become apparent when evaluating the HDX results for the presence of local and long range interactions. Hirudin(54–65) is a tight binding ligand, and HDX studies confirm that it targets ABE I (Fig. 9). Some modest HDX protection at the autolysis loop and/or near the active site could, at times, be observed in the presence of Hirudin(54–65), PAR3(44–56), and PAR1(49–62).

An important finding from the current HDX studies was that Hirudin(54–65) and the PAR family could both target ABE I; however, the PARs could introduce more extensive long range...
effects across the thrombin surface. The PAR3(44–56) and PAR1(49–62) sequences were shown previously by x-ray crystallography to interact with thrombin ABE I (35, 36). In our HDX control studies, PAR3(44–56) has not been observed to bypass ABE I and move on to bind ABE II.

The long range ABE I to ABE II influences observed with the PAR peptides are complementary to the ABE II to ABE I effects observed with either Fbg/H9253/H11032 or GpIb/H9251 peptides (15, 16). The PAR3(44–56) and PAR1(49–62) peptides induced solvent protection that extended from thrombin ABE I over to positions 85–99 (ABE II), 106–116 (segment between ABE I and ABE II), and 173–181 (ABE II near the active site). PAR3(44–56) promoted greater effects over to positions 135–149D (autolysis loop) and 202–207 (segment in the B chain linking over toward the A chain; Fig. 9).

For ABE I ligands, the position 106–116 HDX effects appear to be most dominant for PAR3(44–56). The 106–116 segment is part of a β-strand located antiparallel to a strand near the N terminus of ABE II residues 85–99. Intriguingly, the ABE II ligands Fbg γ' and GpIbα also take advantage of 106–116 (15, 16). The β-strand may serve as a pathway to transmit information between the two thrombin exosites.

The reasons why PAR1 and PAR3 segments induce greater long range conformational effects on thrombin than Hirudin(54–65) are valuable to consider. Prior studies demonstrated that the presence of GpIbα at thrombin ABE II leads to enhanced cleavage of PAR 1 (44, 45). PAR1 hydrolysis within the thrombin active site region benefits from anchoring a distal portion of PAR1 to ABE I. To achieve appropriate regulation of this GpIbα-IIa-PAR1 system on platelets, it may be advantageous to have communication between the two exosites and also with the active site. Hirudin, by contrast, is an effective inhibitor, and the 54–65 segment may predominantly focus on targeting ABE I and influencing the active site. Less is known about the effects of PAR3 on thrombin conformation. Interestingly, PAR3 has been reported to serve as a cofactor in promoting interactions between murine thrombin and PAR4 (46). X-ray crystallography has documented that PAR3 peptide binding at thrombin ABE I influences the orientation of the 60s insertion loop and thus PAR 4 access to the catalytic site (35).

**Introducing a Covalently Bound Inhibitor**—Placing an inhibitor at the thrombin active site also has distinct consequences. Solution NMR studies by Lechtenberg et al. (20) suggest that PPACK helps to establish the functional core of thrombin and aids in reducing the solution dynamics of this serine protease. Bringing in Hirudin(54–65) at ABE I introduces further conformational changes thus preparing thrombin for utilizing its substrates and ligands (20). The first backbone dynamics study on PPACK-thrombin was recently reported by Fuglestad et al. (21) and involved a combination of NMR relaxation rate measurements and accelerated molecular dynamics simulations. Their research confirmed that the functional core of the serine
protease is stabilized upon PPACK binding; however, the surface loops remain surprisingly dynamic. Moreover, these loops exhibit motions on multiple time scales. The thrombin autolysis loop is a clear participant in this phenomenon. Other regions include the 90s and 60s loops, the loops involved in the Na+/H11001 site, and the thrombin A-chain. Such a dynamic thrombin environment may be crucial for promoting communication between the active site and the anion-binding exosites (21).

HDX coupled with mass spectrometry provides an opportunity to further monitor the solvent accessibility changes that occur with a series of thrombin-ligand complexes in the presence of PPACK. The HDX studies carried out here and in earlier studies (15, 28) reveal that the presence of PPACK leads primarily to solvent protection in ABE II regions near the active site and also modest effects at the autolysis loop (15, 28). The current HDX studies indicate that the ABE I ligands PAR3(44–56) (Protein Data Bank code 2PUX) are depicted as black sticks. The figure was prepared with PyMOL.

FIGURE 8. Deuterium incorporation when both exosites are occupied. The bars in the graphs correspond to deuterium incorporation of free thrombin (white), binary thrombin-Hirudin(54–65) complex (gray), binary thrombin-GpIb(269–286) complex (striped white), binary thrombin-γ(410–427) complex (dotted white), ternary thrombin-Hirudin(54–65)-GpIb(269–286) complex (striped gray), and ternary thrombin-Hirudin(54–65)-γ(410–427) complex (dotted gray). Values for both 1 and 10 min of deuteration are displayed. The error bars correspond to standard deviations for three independent trials.

FIGURE 9. The HDX binding patterns of various thrombin ligands. Thrombin segments that were protected from solvent exchange following 10 min of deuteration are colored in red. The observed HDX effects were statistically different from the values obtained with free thrombin at a level of p < 0.001. The individual ligands bound to thrombin including GpIb(269–286) (Protein Data Bank code 1P8V), Hirudin(54–65) (Protein Data Bank code 1HAH), and PAR3(44–56) (Protein Data Bank code 2PUX) are depicted as black sticks. The figure was prepared with PyMOL.
**Exosite Interactions in Thrombin**

### Table 1

| Ligand          | Target site | Long range influences |
|-----------------|-------------|-----------------------|
| TMEGF56<sup>a</sup> | ABE I       | Autolysis loop        |
| PAR3(44–56)     | ABE I       | ABE II (90s loop, 85–99), autolysis loop |
|                 |             | ABE II (near the active site, 173–181) 106 to 116, 202 to 207, –13 to –4 |
| PAR1(49–62)     | ABE I       | ABE II (90s loop, 85–99) ABE II (near the active site, 173–181) 106–116 |
| Hirudin(54–65)  | ABE I       | ABE II (near the active site, 173–181) Autolysis loop |
| TMEGF56<sup>a</sup> | ABE I       | Autolysis loop        |
| Thrombin mAb<sup>b</sup> | ABE I   | 108–116               |
| Gplbo<sup>c</sup> (269–286)<sup>d</sup> | ABE II | 106 to 116, 202 to 207, –13 to –4 ABE I(65–84) |
| Fbg γ(410–427)<sup>d</sup> | ABE II | 106 to 116, 202 to 207, –13 to –4 ABE I(65–84) |

<sup>a</sup> Thrombomodulin EGF domains (17, 19).
<sup>b</sup> Monoclonal antibody against human thrombin (47).
<sup>c</sup> Gplbo fragment (16).
<sup>d</sup> Fibrinogen γ fragment (15).

*Examining the Influences of Dual Occupancy*—Our studies provide the first examples of probing ligand binding to both anion-binding exosites using HDX. In complementary fluorescence-based approaches, dual occupancies with Fbg γ’ peptide or Gplbo at ABE II and then Hirudin(54–65) or DNA aptamer at ABE I have been observed (10, 11). The HDX studies provide the advantage of demonstrating that Hirudin(54–65) focuses its effects on ABE I and then allowing Fbg γ’ or Gplbo peptides to target specific ABE II segments and influence other more distant regions (Fig. 9). Interestingly, the Fbg γ’ peptide has been shown by De Cris-tofaro and co-workers (11) to inhibit thrombin cleavage of PAR1(38–60), leading to a decrease in $k_{cat}$ value. This PAR1 sequence extends from the active site to ABE I. Hydrolysis of full-length PAR1 on intact platelets is also hindered by increasing concentrations of Fbg γ’ peptide. By contrast, Gplbo binding can promote hydrolysis of PAR1 on platelets (44). Similar effects were not observed with a comparable PAR4 peptide substrate sequence (11). The Fbg γ’ peptide may be propagating an effect over to the active site region that has greater influence on the PAR1 LDPR sequence than the PAR4 PAPR sequence. PAR domains with affinities more closely approaching that of Hirudin would allow other dual occupancy complexes to be probed by HDX approaches.

*Comparing and Contrasting Ligands That Target Anion-binding Exosites*—To better understand the characteristics and functions of thrombin exosites, it is valuable to also consider other ligands that have been studied. Hirudin(54–65), a monoclonal antibody against human thrombin (47), TMEGF45 (thrombomodulin fourth and fifth EGF domains) (17), TMEGF56 (thrombomodulin fifth and sixth EGF domains) (17), PAR3(44–56), and PAR1(49–62) all interact at the same region of thrombin ABE I, but they do not all exhibit the same influences on the solvent accessibility properties of thrombin (Table 1). Hirudin(54–65) focuses on ABE I and then has only a very modest influence over to the autolysis loop and ABE II(173–181). TMEGF45 and TMEGF56 both bind to ABE I via the fifth EGF domain and affect the solvent accessibility of the autolysis loop (17, 37).

TMEGF45 has the added benefit of also promoting long range influences over to the 90s loop (within ABE II residues 85–99) (14, 17, 18). Interestingly, TMEGF45 supports thrombin activation of protein C, and residues in the 90s region (Arg<sup>93</sup>, Arg<sup>97</sup>, and Arg<sup>101</sup>) are important in the activation process (48). This benefit occurs even though TMEGF45 and TMEGF56 bind with similar affinity to thrombin. These HDX data suggest that the presence of the EGF4 domain contributes to the conformational events involving the 90s loop (17). In support of these HDX observations, conventional and accelerated molecular dynamics studies have recently revealed an allosteric pathway involving key components of thrombin that is present only in the slow time scale of tens of microseconds (49). This pathway contains a network of correlated motions linking the fourth and fifth EGF domains and surface loops near the thrombin active site region.

The current HDX studies suggest that PAR3(44–56) and PAR1(49–62) exhibit some conformational properties similar to those of TMEGF45. Both PAR peptides promote long range influences over to the 90s loop (within ABE II residues 85–99), and PAR3(44–56) has a greater influence on the autolysis-loop. PAR3(44–56) and PAR1(49–62) also influence other thrombin segments including residues 106–116 and 173–181. The 106–116 segment is particularly affected. Further studies are needed to evaluate the extent to which these different segments may influence PAR binding, ABE II ligand binding, and/or functional roles in thrombin. The focus of the HDX approach is to identify regions that undergo conformational events reflected in terms of solvent accessibility changes.

A final class of ABE I targeted ligands that has been probed includes a monoclonal antibody against human thrombin (47). HDX studies reveal that the epitope for this antibody involves ABE I and the segment 108–116. Curiously, there are no other long range effects.

In contrast to the ABE I-directed ligands mentioned above, Fbg γ’ and Gplbo generated similar local and long range effects following binding to ABE II (15, 16). A review of different thrombin-ligand complexes reveals that the ABE II binding surface is somewhat broader than that of ABE I (3). Whether other ABE II ligands can achieve a different set of long range consequences is still to be seen (3, 10).

*Thrombin Is Highly Dynamic*—Solution-based evidence continues to accumulate supporting the proposal that free thrombin is highly dynamic and thus may adopt multiple conformations. Thrombin may have properties similar to that of ubiquitin, a protein recently shown to contain a rich ground state ensemble (50, 51). The ubiquitin ensemble has an array of conformers that interconvert with each other on the low microsecond time scale (51). Fuglestad et al. (21) already have evidence that thrombin contains amino acids that exhibit motions in this supra $\tau_*$ time scale. For the thrombin system, substrate or cofactors may seek out select conformations and further promote thrombin to adopt particular structural and dynamical features. Some of these free thrombin conformations may be trapped in the thrombin-bound x-ray crystal structures already...
being reported. Furthermore, key conformational states of thrombin have been identified in solution (52–55).

NMR studies have revealed that the functional core of thrombin is stabilized upon PPACK binding. Intriguingly, the surface loops remain dynamic with motions on multiple time scales (21). Additional ligand binding has the opportunity to further influence the conformational and functional properties of thrombin (20). Some of the different interpretations about the presence and consequences of interexosite communication may well be related to the ligands examined. Hydrogen-deuterium exchange, NMR ligand titrations, relaxation rate studies on amino acid backbone events, and molecular dynamics methods all contribute additional strategies for probing the conformational properties of thrombin (15–17, 20, 21, 49).

Conclusions—The HDX studies carried out in the current project indicate that ligands that target a particular thrombin exosite do not all promote identical conformational consequences. Similar and distinct patterns of local and long range effects were observed in the presence of the ABE I ligands Hirudin (54–65), PAR3 (44–56), and PAR1 (49–62). Occupation of the active site with the inhibitor PPACK may further influence the HDX effects observed. Moreover, it is possible to occupy ABE I with Hirudin (54–65) and still get effective binding of Gplbα and Fbg γ’ peptides to ABE II. As with the single ligands, individual regions of thrombin that are affected can be mapped out. The local and long range effects of these ternary complexes are maintained, thus permitting the utilization of interexosite communication. The knowledge gained may later be used to design new ligand-based therapeutics that exert an effect at a specific thrombin site or that could also influence a distant region of the enzyme.

Acknowledgments—We are thankful for the guidance and assistance of M. Merchant and D. Wilkie (University of Louisville Clinical Proteomics Center) in performing the MS/MS analysis on an ABI 4700 MALDI-TOF/TOF mass spectrometer. We appreciate helpful discussions and critical evaluations of this work from Donghan Lee, M. C. Yappert, R. T. Woofter, P. G. Doiphode, and M. A. Jadhav.

REFERENCES
1. Di Cera, E. (2008) Thrombin. Mol. Aspects Med. 29, 203–254
2. Lane, D. A., Philippou, H., and Huntington, J. A. (2005) Directing thrombin. Blood 106, 2605–2612
3. Bock, P. E., Panizzi, P., and Verhamme, I. M. (2007) Esoxides in the substrate specificity of blood coagulation reactions. J. Thromb. Haemost. 5, 81–94
4. Dang, Q. D., Sabetta, M., and Di Cera, E. (1997) Selective loss of fibrinogen clotting in a loop-less thrombin. J. Biol. Chem. 272, 19649–19651
5. Bode, W., Turk, D., and Karshikov, A. (1992) The refined 1.9 Å X-ray crystal structure of b-Pro-Arg chloromethylketone-inhibited human α-thrombin. Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1, 426–471
6. Sidhu, P. S., Liang, A., Mehta, A. Y., Abdel Aziz, M. H., Zhou, Q., and Desai, U. R. (2011) Rational design of potent, small, synthetic allosteric inhibitors of thrombin. J. Med. Chem. 54, 5522–5531
7. Verhamme, I. M., Olson, S. T., Tollefsen, D. M., and Bock, P. E. (2002) Binding of esoxide ligands to human thrombin. Re-evaluation of allosteric linkage between thrombin exosites I and II. J. Biol. Chem. 277, 6788–6798
8. Ng, N. M., Quinsey, N. S., Matthews, A. Y., Kaiserman, D., Wijeyewickrema, L. C., Bird, P. I., Thompson, P. E., and Pike, R. N. (2009) The effects of esoxide occupancy on the substrate specificity of thrombin. Arch. Biochem. Biophys. 489, 48–54
9. Ye, J., Liu, W. W., Esmon, C. T., and Johnson, A. E. (1992) The fifth and sixth growth factor-like domains of thrombomodulin bind to the anion-binding exosite of thrombin and alter its specificity. J. Biol. Chem. 267, 11023–11028
10. Li, W., Johnson, D. J., Adams, T. E., Pozzi, N., De Filippis, V., and Huntington, J. A. (2010) Thrombin inhibition by serpins disrupts exosite II. J. Biol. Chem. 285, 38621–38629
11. Lancellotti, S., Rutella, S., De Filippis, V., Pozzi, N., Rocca, B., and De Cristofaro, R. (2008) Fibrinogen-elongated γ chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors. J. Biol. Chem. 283, 30193–30204
12. Fredenburg, J. C., Stafford, A. R., and Wetz, J. I. (1997) Evidence for allosteric linkage between exosites I and 2 of thrombin. J. Biol. Chem. 272, 25493–25499
13. Petrera, N. S., Stafford, A. R., Leslie, B. A., Kretz, C. A., Fredenburg, J. C., and Weitz, J. I. (2009) Long range communication between exosites I and 2 modulates thrombin function. J. Biol. Chem. 284, 25620–25629
14. Mandell, J. G., Falick, A. M., and Komives, E. A. (1998) Identification of protein–protein interfaces by decreased amide proton solvent accessibility. Proc. Natl. Acad. Sci. U.S.A. 95, 14705–14710
15. Sabo, T. M., Farrell, D. H., and Maurer, M. C. (2006) Conformational analysis of γ’ peptide (410–427) interactions with thrombin anion binding exosite II. Biochemistry 45, 7434–7445
16. Sabo, T. M., and Maurer, M. C. (2009) Biophysical investigation of Gplbα binding to thrombin anion binding exosite II. Biochemistry 48, 7110–7122
17. Koepe, J. R., Seitoa, A., Mather, T., and Komives, E. A. (2005) Thrombomodulin tightens the thrombin active site loops to promote protein C activation. Biochemistry 44, 14784–14791
18. Mandell, J. G., Falick, A. M., and Komives, E. A. (1998) Measurement of amide hydrogen exchange by MALDI-TOF mass spectrometry. Anal. Chem. 70, 3987–3995
19. Mandell, J. G., Baerga-Ortiz, A., Akashi, S., Takio, K., and Komives, E. A. (2001) Solvent accessibility of the thrombin-thrombomodulin interface. J. Mol. Biol. 306, 575–589
20. Lechtenberg, B. C., Johnson, D. J., Freund, S. M., and Huntington, J. A. (2010) NMR resonance assignments of thrombin reveal the conformational and dynamic effects of ligation. Proc. Natl. Acad. Sci. U.S.A. 107, 14087–14092
21. Fuglestad, B., Gasper, P. M., Tonelli, M., McCammon, J. A., Markwick, P. R., and Komives, E. A. (2012) The dynamic structure of thrombin in solution. Biophys. J. 103, 79–88
22. Kroh, H. K., Tans, G., Nicolaes, G. A., Rosing, J., and Bock, P. E. (2007) Expression of allosteric linkage between the sodium ion binding site and exosite I of thrombin during prothrombin activation. J. Biol. Chem. 282, 16095–16104
23. Anderson, P. J., Nesset, A., Dharmawardana, K. R., and Bock, P. E. (2000) Characterization of proexosite I on prothrombin. J. Biol. Chem. 275, 16428–16434
24. Krem, M. M., and Di Cera, E. (2003) Dissecting substrate recognition by thrombin using the inactive mutant S195A. Biophys. Chem. 100, 315–323
25. De Marco, L., Mazzucato, M., Masotti, A., and Ruggeri, Z. M. (1994) Localization and characterization of an α-thrombin-binding site on platelet glycoprotein IIb/IIIa. J. Biol. Chem. 269, 6478–6484
26. Lovely, R. S., Moaddel, M., and Farrell, D. H. (2003) Fibrinogen γ’ chain binds thrombin exosite II. J. Thromb. Haemost 1, 124–131
27. Trumbo, T. A., and Maurer, M. C. (2000) Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J. Biol. Chem. 275, 20627–20631
28. Croy, C. H., Koepe, J. R., Bergqvist, S., and Komives, E. A. (2004) Allosteric changes in solvent accessibility observed in thrombin upon active site occupation. Biochemistry 43, 5246–5255
29. Ni, F., Meinwald, Y. C., Vásquez, M., and Scheraga, H. A. (1989) High-resolution NMR studies of fibrinogen-like peptides in solution. Structure
of a thrombin-bound peptide corresponding to residues 7–16 of the Aa chain of human fibrinogen. Biochemistry 28, 3094–3105

30. Ni, F., Ripoll, D. R., Martin, P. D., and Edwards, B. F. (1992) Solution structure of a platelet receptor peptide bound to bovine α-thrombin. Biochemistry 31, 11551–11557

31. Hofsteenge, J., Braun, P. J., and Stone, S. R. (1988) Enzymatic properties of proteolytic derivatives of human α-thrombin. Biochemistry 27, 2144–2151

32. Hoofnagle, A. N., Resing, K. A., and Ahn, N. G. (2003) Protein analysis by hydrogen exchange mass spectrometry. Annu. Rev. Biophys. Biomol. Struct. 32, 1–25

33. Xu, H., Bush, L. A., Pineda, A. O., Caccia, S., and Di Cera, E. (2005) Thrombomodulin activation of slow thrombin. J. Biol. Chem. 280, 13593–13598

34. Rydel, T. J., Ravichandran, K. G., Tulinsky, A., Bode, W., Huber, R., Roitsch, C., and Fenton, J. W., 2nd. (1990) The structure of a complex of recombinant hirudin and human α-thrombin. Science 249, 277–280

35. Bah, A., Chen, Z., Bush-Pelc, L. A., Mathews, F. S., and Di Cera, E. (2007) Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc. Natl. Acad. Sci. U.S.A. 104, 11603–11608

36. Gandhi, P. S., Chen, Z., and Di Cera, E. (2010) Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1. J. Biol. Chem. 285, 15393–15398

37. Fuentes-Prior, P., Iwanaga, Y., Huber, R., Pagila, R., Ruminnik, G., Seto, M., Morser, J., Light, D. R., and Bode, W. (2000) Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 404, 518–525

38. Mengwasser, K. E., Bush, L. A., Shih, P., Cantwell, A. M., and Di Cera, E. (2005) Hirudin binding reveals key determinants of thrombin allostery. J. Biol. Chem. 280, 26997–27003

39. Ayala, Y. M., Cantwell, A. M., Rose, T., Bush, L. A., Arosio, D., and Di Cera, E. (2001) Molecular mapping of thrombin-receptor interactions. Proteins 45, 107–116

40. Pineda, A. O., Cantwell, A. M., Bush, L. A., Rose, T., and Di Cera, E. (2002) The thrombin epitope recognizing thrombomodulin is a highly cooperative hot spot in exosite I. J. Biol. Chem. 277, 32015–32019

41. Hall, S. W., Nagashima, M., Zhao, L., Morser, J., and Leung, L. L. (1999) Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. J. Biol. Chem. 274, 25510–25516

42. Adams, T. E., Li, W., and Huntington, J. A. (2009) Molecular basis of thrombomodulin activation of slow thrombin. J. Thromb. Haemost. 7, 1688–1695

43. Parry, M. A., Stone, S. R., Hofsteenge, J., and Jackman, M. P. (1993) Evidence for common structural changes in thrombin induced by active-site or exosite binding. Biochem. J. 290, 665–670

44. De Candia, E., Hall, S. W., Rutella, S., Landolfi, R., Andrews, R. K., and De Cristofaro, R. (2001) Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J. Biol. Chem. 276, 4692–4698

45. De Cristofaro, R., De Candia, E., Landolfi, R., Rutella, S., and Hall, S. W. (2001) Structural and functional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib. Biochemistry 40, 13268–13273

46. Nakahashi-Matsui, M., Zheng, Y. W., Sulciner, D. J., Weiss, E. J., Ludeman, M. J., and Coughlin, S. R. (2000) PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404, 609–613

47. Baerga-Ortiz, A., Hughes, C. A., Mandell, J. G., and Komives, E. A. (2002) Epitope mapping of a monoclonal antibody against human thrombin by H/D-exchange mass spectrometry reveals selection of a diverse sequence in a highly conserved protein. Protein Sci. 11, 1300–1308

48. He, X., Ye, J., Esmon, C. T., and Rezaie, A. R. (1997) Influence of arginines 93, 97, and 101 of thrombin to its functional specificity. Biochemistry 36, 8969–8976

49. Gasper, P. M., Fuglestad, B., Komives, E. A., Markwick, P. R., and McCammon, J. A. (2012) Allosteric networks in thrombin distinguish procoagulant vs. anticoagulant activities. Proc. Natl. Acad. Sci. U.S.A., 109, 21216–21222

50. Lange, O. F., Lakomek, N. A., Farès, C., Schröder, G. F., Walter, K. F., Becker, S., Meiler, J., Grubmüller, H., Griesinger, C., and de Groot, B. L. (2008) Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. Science 320, 1471–1475

51. Ban, D., Funk, M., Gulich, R., Egger, D., Sabo, T. M., Walter, K. F., Fenwick, R. B., Giller, K., Pichiari, F., de Groot, B. L., Lange, O. F., Grubmüller, H., Salvatella, X., Wolf, M., Loidl, A., Kree, R., Becker, S., Lakomek, N. A., Lee, D., Lunkenheimer, P., and Griesinger, C. (2011) Kinetics of conformational sampling in ubiquitin. Angew. Chem. Int. Ed. Engl. 50, 11437–11440

52. Bradford, H. N., and Krishnaswamy, S. (2012) Meizothrombin is an unexpectedly zymogen-like variant of thrombin. J. Biol. Chem. 287, 30414–30425

53. Pozzi, N., Vogt, A. D., Gobara, D. W., and Di Cera, E. (2012) Conformational selection in trypsin-like proteases. Curr. Opin. Struct. Biol. 22, 421–431

54. Vogt, A. D., and Di Cera, E. (2012) Conformational selection or induced fit? A critical appraisal of the kinetic mechanism. Biochemistry 51, 5894–5902

55. Kamath, P., Huntington, J. A., and Krishnaswamy, S. (2010) Ligand binding shuttles thrombin along a continuum of zymogen-like and proteinase-like states. J. Biol. Chem. 285, 28651–28658